Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. (Q40472458)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Marcelo E Bigal

1

object named as

Marcelo E Bigal

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Richard B. Lipton

10

object named as

Richard B Lipton

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

8

object named as

Rami Burstein

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

2

object named as

David W Dodick

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Stephen D. Silberstein

4

object named as

Stephen D Silberstein

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Alan M Rapoport

3

object named as

Alan M Rapoport

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

6

object named as

Ronghua Yang

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

7

object named as

Pippa S Loupe

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Yuju Ma

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Lawrence C Newman

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

29 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1081-1090

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The International Classification of Headache Disorders, 3rd edition (beta version)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical course in migraine: conceptualizing migraine transformation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Migraine prevalence, disease burden, and the need for preventive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The family impact of migraine: population-based studies in the USA and UK

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lifting the burden: The global campaign against headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for chronic daily headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Is CGRP a marker for chronic migraine?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Possible sites of action of the new calcitonin gene-related peptide receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Migraine prophylaxis with divalproex

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Topiramate for migraine prevention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900249-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(15)00249-5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40472458&oldid=1746273371"